Historical Valuation
Standard BioTools Inc (LAB) is now in the Overvalued zone, suggesting that its current forward PS ratio of 6.28 is considered Overvalued compared with the five-year average of -9.67. The fair price of Standard BioTools Inc (LAB) is between 0.68 to 1.33 according to relative valuation methord. Compared to the current price of 1.57 USD , Standard BioTools Inc is Overvalued By 17.7%.
Relative Value
Fair Zone
0.68-1.33
Current Price：1.57
17.7%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Standard BioTools Inc (LAB) has a current Price-to-Book (P/B) ratio of 1.22. Compared to its 3-year average P/B ratio of 0.09 , the current P/B ratio is approximately 1262.37% higher. Relative to its 5-year average P/B ratio of 1.10, the current P/B ratio is about 11.22% higher. Standard BioTools Inc (LAB) has a Forward Free Cash Flow (FCF) yield of approximately -20.15%. Compared to its 3-year average FCF yield of -28.16%, the current FCF yield is approximately -28.43% lower. Relative to its 5-year average FCF yield of -29.34% , the current FCF yield is about -31.32% lower.
P/B
Median3y
0.09
Median5y
1.10
FCF Yield
Median3y
-28.16
Median5y
-29.34
Competitors Valuation Multiple
AI Analysis for LAB
The average P/S ratio for LAB competitors is 7.33, providing a benchmark for relative valuation. Standard BioTools Inc Corp (LAB.O) exhibits a P/S ratio of 6.28, which is -14.27% above the industry average. Given its robust revenue growth of -56.52%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for LAB
1Y
3Y
5Y
Market capitalization of LAB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LAB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LAB currently overvalued or undervalued?
Standard BioTools Inc (LAB) is now in the Overvalued zone, suggesting that its current forward PS ratio of 6.28 is considered Overvalued compared with the five-year average of -9.67. The fair price of Standard BioTools Inc (LAB) is between 0.68 to 1.33 according to relative valuation methord. Compared to the current price of 1.57 USD , Standard BioTools Inc is Overvalued By 17.70% .
What is Standard BioTools Inc (LAB) fair value?
LAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Standard BioTools Inc (LAB) is between 0.68 to 1.33 according to relative valuation methord.
How does LAB's valuation metrics compare to the industry average?
The average P/S ratio for LAB's competitors is 7.33, providing a benchmark for relative valuation. Standard BioTools Inc Corp (LAB) exhibits a P/S ratio of 6.28, which is -14.27% above the industry average. Given its robust revenue growth of -56.52%, this premium appears unsustainable.
What is the current P/B ratio for Standard BioTools Inc (LAB) as of Jan 10 2026?
As of Jan 10 2026, Standard BioTools Inc (LAB) has a P/B ratio of 1.22. This indicates that the market values LAB at 1.22 times its book value.
What is the current FCF Yield for Standard BioTools Inc (LAB) as of Jan 10 2026?
As of Jan 10 2026, Standard BioTools Inc (LAB) has a FCF Yield of -20.15%. This means that for every dollar of Standard BioTools Inc’s market capitalization, the company generates -20.15 cents in free cash flow.
What is the current Forward P/E ratio for Standard BioTools Inc (LAB) as of Jan 10 2026?
As of Jan 10 2026, Standard BioTools Inc (LAB) has a Forward P/E ratio of -23.09. This means the market is willing to pay $-23.09 for every dollar of Standard BioTools Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Standard BioTools Inc (LAB) as of Jan 10 2026?
As of Jan 10 2026, Standard BioTools Inc (LAB) has a Forward P/S ratio of 6.28. This means the market is valuing LAB at $6.28 for every dollar of expected revenue over the next 12 months.